{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["HBV", "HBsAg", "YZH-106", "degradation"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "39066313", "DateCompleted": {"Year": "2024", "Month": "07", "Day": "28"}, "DateRevised": {"Year": "2024", "Month": "07", "Day": "29"}, "Article": {"Language": ["eng"], "ELocationID": ["1151", "10.3390/v16071151"], "ArticleDate": [{"Year": "2024", "Month": "07", "Day": "17"}], "Journal": {"ISSN": "1999-4915", "JournalIssue": {"Volume": "16", "Issue": "7", "PubDate": {"Year": "2024", "Month": "Jul", "Day": "17"}}, "Title": "Viruses", "ISOAbbreviation": "Viruses"}, "ArticleTitle": "Rupestonic Acid Derivative YZH-106 Promotes Lysosomal Degradation of HBV L- and M-HBsAg via Direct Interaction with PreS2 Domain.", "Abstract": {"AbstractText": ["Hepatitis B surface antigen (HBsAg) is not only the biomarker of hepatitis B virus (HBV) infection and expression activity in hepatocytes, but it also contributes to viral specific T cell exhaustion and HBV persistent infection. Therefore, anti-HBV therapies targeting HBsAg to achieve HBsAg loss are key approaches for an HBV functional cure. In this study, we found that YZH-106, a rupestonic acid derivative, inhibited HBsAg secretion and viral replication. Further investigation demonstrated that YZH-106 promoted the lysosomal degradation of viral L- and M-HBs proteins. A mechanistic study using Biacore and docking analysis revealed that YZH-106 bound directly to the PreS2 domain of L- and M-HBsAg, thereby blocking their entry into the endoplasmic reticulum (ER) and promoting their degradation in cytoplasm. Our work thereby provides the basis for the design of a novel compound therapy to target HBsAg against HBV infection."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China."}], "LastName": "Liu", "ForeName": "Lanlan", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China."}, {"Identifier": [], "Affiliation": "University of Chinese Academy of Sciences, Beijing 100101, China."}], "LastName": "Wang", "ForeName": "Haoyu", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China."}], "LastName": "Liu", "ForeName": "Lulu", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China."}, {"Identifier": [], "Affiliation": "University of Chinese Academy of Sciences, Beijing 100101, China."}], "LastName": "Cheng", "ForeName": "Fang", "Initials": "F"}, {"Identifier": ["0000-0003-4652-6879"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, China."}], "LastName": "Aisa", "ForeName": "Haji Akber", "Initials": "HA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China."}], "LastName": "Li", "ForeName": "Changfei", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China."}, {"Identifier": [], "Affiliation": "University of Chinese Academy of Sciences, Beijing 100101, China."}], "LastName": "Meng", "ForeName": "Songdong", "Initials": "S"}], "GrantList": [{"GrantID": "2022YFC2304203", "Agency": "National Key R&D Program of China", "Country": ""}, {"GrantID": "2018HS", "Agency": "Industrial innovation team grant from Foshan Industrial Technology Research Institute", "Country": ""}, {"GrantID": "32070163", "Agency": "National Natural Science Foundation of China", "Country": ""}, {"Agency": "Foshan High-level Hospital construction DengFeng plan", "Country": ""}, {"Agency": "Guangdong Province biomedical innovation platform construction project tumor immunotherapy", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Viruses", "NlmUniqueID": "101509722", "ISSNLinking": "1999-4915"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Hepatitis B Surface Antigens"}, {"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "presurface protein 2, hepatitis B surface antigen"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Precursors"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug effects", "genetics"], "DescriptorName": "Hepatitis B virus"}, {"QualifierName": ["metabolism"], "DescriptorName": "Hepatitis B Surface Antigens"}, {"QualifierName": ["metabolism"], "DescriptorName": "Lysosomes"}, {"QualifierName": ["drug effects"], "DescriptorName": "Virus Replication"}, {"QualifierName": ["virology", "drug therapy"], "DescriptorName": "Hepatitis B"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": [], "DescriptorName": "Proteolysis"}, {"QualifierName": [], "DescriptorName": "Hep G2 Cells"}, {"QualifierName": ["virology", "metabolism"], "DescriptorName": "Hepatocytes"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Protein Binding"}, {"QualifierName": [], "DescriptorName": "Protein Precursors"}], "CoiStatement": "The authors declare no conflicts of interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Seeger C., Mason W.S. Molecular Biology of Hepatitis B Virus Infection. Virology. 2015;479\u2013480:672\u2013686. doi: 10.1016/j.virol.2015.02.031.", "ArticleIdList": ["10.1016/j.virol.2015.02.031", "PMC4424072", "25759099"]}, {"Citation": "Tsukuda S., Watashi K. Hepatitis B Virus Biology and Life Cycle. Antivir. Res. 2020;182:104925. doi: 10.1016/j.antiviral.2020.104925.", "ArticleIdList": ["10.1016/j.antiviral.2020.104925", "32866519"]}, {"Citation": "Cornberg M., Wong V.W.-S., Locarnini S., Brunetto M., Janssen H.L.A., Chan H.L.-Y. The Role of Quantitative Hepatitis B Surface Antigen Revisited. J. Hepatol. 2017;66:398\u2013411. doi: 10.1016/j.jhep.2016.08.009.", "ArticleIdList": ["10.1016/j.jhep.2016.08.009", "27575311"]}, {"Citation": "Lan P., Zhang C., Han Q., Zhang J., Tian Z. Therapeutic Recovery of Hepatitis B Virus (HBV)-Induced Hepatocyte-Intrinsic Immune Defect Reverses Systemic Adaptive Immune Tolerance. Hepatology. 2013;58:73\u201385. doi: 10.1002/hep.26339.", "ArticleIdList": ["10.1002/hep.26339", "23447417"]}, {"Citation": "Van der Molen R.G., Sprengers D., Binda R.S., de Jong E.C., Niesters H.G.M., Kusters J.G., Kwekkeboom J., Janssen H.L.A. Functional Impairment of Myeloid and Plasmacytoid Dendritic Cells of Patients with Chronic Hepatitis B. Hepatology. 2004;40:738\u2013746. doi: 10.1002/hep.20366.", "ArticleIdList": ["10.1002/hep.20366", "15349914"]}, {"Citation": "Kondo Y., Ninomiya M., Kakazu E., Kimura O., Shimosegawa T. Hepatitis B Surface Antigen Could Contribute to the Immunopathogenesis of Hepatitis B Virus Infection. ISRN Gastroenterol. 2013;2013:935295. doi: 10.1155/2013/935295.", "ArticleIdList": ["10.1155/2013/935295", "PMC3562682", "23401786"]}, {"Citation": "Mak L.-Y., Seto W.-K., Hui R.W.-H., Fung J., Wong D.K.-H., Lai C.-L., Yuen M.-F. Fibrosis Evolution in Chronic Hepatitis B e Antigen-Negative Patients across a 10-Year Interval. J. Viral Hepat. 2019;26:818\u2013827. doi: 10.1111/jvh.13095.", "ArticleIdList": ["10.1111/jvh.13095", "30895682"]}, {"Citation": "Cornberg M., Lok A.S.-F., Terrault N.A., Zoulim F. 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B\u2014Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference\u2021. J. Hepatol. 2020;72:539\u2013557. doi: 10.1016/j.jhep.2019.11.003.", "ArticleIdList": ["10.1016/j.jhep.2019.11.003", "31730789"]}, {"Citation": "Tout I., Loureiro D., Mansouri A., Soumelis V., Boyer N., Asselah T. Hepatitis B Surface Antigen Seroclearance: Immune Mechanisms, Clinical Impact, Importance for Drug Development. J. Hepatol. 2020;73:409\u2013422. doi: 10.1016/j.jhep.2020.04.013.", "ArticleIdList": ["10.1016/j.jhep.2020.04.013", "32333923"]}, {"Citation": "Bazinet M., P\u00e2ntea V., Cebotarescu V., Cojuhari L., Jimbei P., Albrecht J., Schmid P., Le Gal F., Gordien E., Krawczyk A., et al. Safety and Efficacy of REP 2139 and Pegylated Interferon Alfa-2a for Treatment-Naive Patients with Chronic Hepatitis B Virus and Hepatitis D Virus Co-Infection (REP 301 and REP 301-LTF): A Non-Randomised, Open-Label, Phase 2 Trial. Lancet Gastroenterol. Hepatol. 2017;2:877\u2013889. doi: 10.1016/S2468-1253(17)30288-1.", "ArticleIdList": ["10.1016/S2468-1253(17)30288-1", "28964701"]}, {"Citation": "Hui R.W.-H., Mak L.-Y., Seto W.-K., Yuen M.-F. RNA Interference as a Novel Treatment Strategy for Chronic Hepatitis B Infection. Clin. Mol. Hepatol. 2022;28:408\u2013424. doi: 10.3350/cmh.2022.0012.", "ArticleIdList": ["10.3350/cmh.2022.0012", "PMC9293617", "35172540"]}, {"Citation": "Kim S.W., Yoon J.S., Lee M., Cho Y. Toward a Complete Cure for Chronic Hepatitis B: Novel Therapeutic Targets for Hepatitis B Virus. Clin. Mol. Hepatol. 2022;28:17\u201330. doi: 10.3350/cmh.2021.0093.", "ArticleIdList": ["10.3350/cmh.2021.0093", "PMC8755466", "34281294"]}, {"Citation": "Sirafil A., Ilhamjan X. Halmurat Regulation of P53, Fas and Bcl-2 Gene Expressions with Artemisia Flavonoid in Human Hepatoma. Chin. J. Biochem. Mol. Biol. 2001;17:226\u2013229. doi: 10.13865/j.cnki.cjbmb.2001.02.020.", "ArticleIdList": ["10.13865/j.cnki.cjbmb.2001.02.020"]}, {"Citation": "Fang M., Chao Q., Lan Y., Liu X., Xu X., Fan Y. Antibacterial Effect of the Extract from Artemisia rupestris L. Food Sci. Technol. 2010;36:160\u2013162. doi: 10.13684/j.cnki.spkj.2011.01.071.", "ArticleIdList": ["10.13684/j.cnki.spkj.2011.01.071"]}, {"Citation": "Zhao J., Aisa H.A. Synthesis and Anti-Influenza Activity of Aminoalkyl rupestonates. Bioorg. Med. Chem. Lett. 2012;22:2321\u20132325. doi: 10.1016/j.bmcl.2012.01.056.", "ArticleIdList": ["10.1016/j.bmcl.2012.01.056", "22341943"]}, {"Citation": "Ma L.-L., Wang H.-Q., Wu P., Hu J., Yin J.-Q., Wu S., Ge M., Sun W.-F., Zhao J.-Y., Aisa H.A., et al. Rupestonic Acid Derivative YZH-106 Suppresses Influenza Virus Replication by Activation of Heme Oxygenase-1-Mediated Interferon Response. Free Radic. Biol. Med. 2016;96:347\u2013361. doi: 10.1016/j.freeradbiomed.2016.04.021.", "ArticleIdList": ["10.1016/j.freeradbiomed.2016.04.021", "27107768"]}, {"Citation": "Li C., Wang Y., Wang S., Wu B., Hao J., Fan H., Ju Y., Ding Y., Chen L., Chu X., et al. Hepatitis B Virus mRNA-Mediated miR-122 Inhibition Upregulates PTTG1-Binding Protein, Which Promotes Hepatocellular Carcinoma Tumor Growth and Cell Invasion. J. Virol. 2013;87:2193\u20132205. doi: 10.1128/JVI.02831-12.", "ArticleIdList": ["10.1128/JVI.02831-12", "PMC3571498", "23221562"]}, {"Citation": "Schinazi R.F., Ehteshami M., Bassit L., Asselah T. Towards HBV Curative Therapies. Liver Int. 2018;38((Suppl. S1)):S102\u2013S114. doi: 10.1111/liv.13656.", "ArticleIdList": ["10.1111/liv.13656", "PMC6481632", "29427479"]}, {"Citation": "Fisicaro P., Barili V., Rossi M., Montali I., Vecchi A., Acerbi G., Laccabue D., Zecca A., Penna A., Missale G., et al. Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches. Front. Immunol. 2020;11:849. doi: 10.3389/fimmu.2020.00849.", "ArticleIdList": ["10.3389/fimmu.2020.00849", "PMC7235343", "32477347"]}, {"Citation": "Yuen M.-F., Chen D.-S., Dusheiko G.M., Janssen H.L.A., Lau D.T.Y., Locarnini S.A., Peters M.G., Lai C.-L. Hepatitis B Virus Infection. Nat. Rev. Dis. Primers. 2018;4:18035. doi: 10.1038/nrdp.2018.35.", "ArticleIdList": ["10.1038/nrdp.2018.35", "29877316"]}, {"Citation": "Ahn S.H., Park Y.N., Park J.Y., Chang H.-Y., Lee J.M., Shin J.E., Han K.-H., Park C., Moon Y.M., Chon C.Y. Long-Term Clinical and Histological Outcomes in Patients with Spontaneous Hepatitis B Surface Antigen Seroclearance. J. Hepatol. 2005;42:188\u2013194. doi: 10.1016/j.jhep.2004.10.026.", "ArticleIdList": ["10.1016/j.jhep.2004.10.026", "15664243"]}, {"Citation": "Lee H.W., Lee J.S., Ahn S.H. Hepatitis B Virus Cure: Targets and Future Therapies. Int. J. Mol. Sci. 2020;22:213. doi: 10.3390/ijms22010213.", "ArticleIdList": ["10.3390/ijms22010213", "PMC7795643", "33379331"]}, {"Citation": "Jiang B., Hildt E. Intracellular Trafficking of HBV Particles. Cells. 2020;9:2023. doi: 10.3390/cells9092023.", "ArticleIdList": ["10.3390/cells9092023", "PMC7563130", "32887393"]}, {"Citation": "Nayagam J.S., Cargill Z.C., Agarwal K. The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis B. Curr. Hepatology Rep. 2020;19:362\u2013369. doi: 10.1007/s11901-020-00548-4.", "ArticleIdList": ["10.1007/s11901-020-00548-4"]}, {"Citation": "Yeo Y.H., Ho H.J., Yang H.-I., Tseng T.-C., Hosaka T., Trinh H.N., Kwak M.-S., Park Y.M., Fung J.Y.Y., Buti M., et al. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-Analysis. Gastroenterology. 2019;156:635\u2013646.e9. doi: 10.1053/j.gastro.2018.10.027.", "ArticleIdList": ["10.1053/j.gastro.2018.10.027", "30342034"]}, {"Citation": "Yuen M.-F., Locarnini S., Given B., Schluep T., Hamilton J., Kalmeijer R., Beumont M., Lenz O., Cloherty G., Jackson K., et al. First Clinical Experience with RNA Interference-Based Triple Combination Therapy in Chronic Hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos(t)Ide Analogue. Hepatology. 2019;70:1489A.", "ArticleIdList": ["0"]}, {"Citation": "Aviram N., Schuldiner M. Targeting and Translocation of Proteins to the Endoplasmic Reticulum at a Glance. J. Cell Sci. 2017;130:4079\u20134085. doi: 10.1242/jcs.204396.", "ArticleIdList": ["10.1242/jcs.204396", "29246967"]}, {"Citation": "Blobel G., Dobberstein B. Transfer of Proteins across Membranes. I. Presence of Proteolytically Processed and Unprocessed Nascent Immunoglobulin Light Chains on Membrane-Bound Ribosomes of Murine Myeloma. J. Cell Biol. 1975;67:835\u2013851. doi: 10.1083/jcb.67.3.835.", "ArticleIdList": ["10.1083/jcb.67.3.835", "PMC2111658", "811671"]}, {"Citation": "Egea P.F., Stroud R.M., Walter P. Targeting Proteins to Membranes: Structure of the Signal Recognition Particle. Curr. Opin. Struct. Biol. 2005;15:213\u2013220. doi: 10.1016/j.sbi.2005.03.007.", "ArticleIdList": ["10.1016/j.sbi.2005.03.007", "15837181"]}, {"Citation": "Gemmer M., F\u00f6rster F. A Clearer Picture of the ER Translocon Complex. J. Cell Sci. 2020;133:jcs231340. doi: 10.1242/jcs.231340.", "ArticleIdList": ["10.1242/jcs.231340", "32019826"]}, {"Citation": "Gerken G., Manns M., Gerlich W.H., Hess G., Meyer zum B\u00fcschenfelde K.H. Pre-S Encoded Surface Proteins in Relation to the Major Viral Surface Antigen in Acute Hepatitis B Virus Infection. Gastroenterology. 1987;92:1864\u20131868. doi: 10.1016/0016-5085(87)90617-2.", "ArticleIdList": ["10.1016/0016-5085(87)90617-2", "3569761"]}, {"Citation": "Bruss V., Vieluf K. Functions of the Internal Pre-S Domain of the Large Surface Protein in Hepatitis B Virus Particle Morphogenesis. J. Virol. 1995;69:6652\u20136657. doi: 10.1128/jvi.69.11.6652-6657.1995.", "ArticleIdList": ["10.1128/jvi.69.11.6652-6657.1995", "PMC189574", "7474074"]}, {"Citation": "Garcia T., Li J., Sureau C., Ito K., Qin Y., Wands J., Tong S. Drastic Reduction in the Production of Subviral Particles Does Not Impair Hepatitis B Virus Virion Secretion. J. Virol. 2009;83:11152\u201311165. doi: 10.1128/JVI.00905-09.", "ArticleIdList": ["10.1128/JVI.00905-09", "PMC2772768", "19706705"]}, {"Citation": "Pfefferkorn M., Schott T., B\u00f6hm S., Deichsel D., Felkel C., Gerlich W.H., Glebe D., Wat C., Pavlovic V., Heyne R., et al. Composition of HBsAg Is Predictive of HBsAg Loss during Treatment in Patients with HBeAg-Positive Chronic Hepatitis B. J. Hepatol. 2021;74:283\u2013292. doi: 10.1016/j.jhep.2020.08.039.", "ArticleIdList": ["10.1016/j.jhep.2020.08.039", "32931877"]}, {"Citation": "Dikic I. Proteasomal and Autophagic Degradation Systems. Annu. Rev. Biochem. 2017;86:193\u2013224. doi: 10.1146/annurev-biochem-061516-044908.", "ArticleIdList": ["10.1146/annurev-biochem-061516-044908", "28460188"]}, {"Citation": "Yamamoto H., Matsui T. Molecular Mechanisms of Macroautophagy, Microautophagy, and Chaperone-Mediated Autophagy. J. Nippon. Med. Sch. 2024;91:2\u20139. doi: 10.1272/jnms.JNMS.2024_91-102.", "ArticleIdList": ["10.1272/jnms.JNMS.2024_91-102", "37271546"]}, {"Citation": "Yang J.Y., Wu Y.-H., Pan M.Y.-C., Chiou Y.-T., Lee R.K.-L., Li T.-N., Wang L.H.-C. Chemical-Induced Degradation of PreS2 Mutant Surface Antigen via the Induction of Microautophagy. Antivir. Res. 2022;207:105417. doi: 10.1016/j.antiviral.2022.105417.", "ArticleIdList": ["10.1016/j.antiviral.2022.105417", "36122619"]}]}], "History": [{"Year": "2024", "Month": "5", "Day": "18"}, {"Year": "2024", "Month": "7", "Day": "13"}, {"Year": "2024", "Month": "7", "Day": "16"}, {"Year": "2024", "Month": "7", "Day": "28", "Hour": "14", "Minute": "51"}, {"Year": "2024", "Month": "7", "Day": "27", "Hour": "10", "Minute": "47"}, {"Year": "2024", "Month": "7", "Day": "27", "Hour": "1", "Minute": "31"}, {"Year": "2024", "Month": "7", "Day": "17"}], "PublicationStatus": "epublish", "ArticleIdList": ["39066313", "PMC11281537", "10.3390/v16071151", "v16071151"]}}]}